title: B cell-directed therapies in type 1 diabetes.
abstract: B cells play a pathogenic role as antigen-presenting cells and autoantibody secretors in the lead up to T cell-mediated autoimmune destruction of insulin-producing β cells in type 1 diabetes (T1D). This has led to significant interest in the use of B cell depletion therapies as a treatment for T1D. In this review, we compare results from five recent studies that used distinct B cell-depleting agents and protocols to successfully prevent and even reverse T1D in the non-obese diabetic (NOD) mouse model. We discuss how information gained from animal studies could be used to improve on the positive outcomes of a completed phase II clinical trial of the B cell-depleting drug rituximab in humans with recent-onset T1D.
authors.affiliation: Immunology Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
authors.forename: Eliana
authors.initials: E
authors.lastname: Mariño
authors.forename: Pablo A
authors.initials: PA
authors.lastname: Silveira
authors.forename: Jessica
authors.initials: J
authors.lastname: Stolp
authors.forename: Shane T
authors.initials: ST
authors.lastname: Grey
mesh_terms: D000818:Animals; D058846:Antibodies, Monoclonal, Murine-Derived / Q000276:immunology / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000276:immunology*; D017322:Clinical Trials, Phase II as Topic; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007700:Kinetics; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab